English
简体中文
Total: £ 56.28
Published Date: 2025-11-07 | Pages: 99 | Tables: 86 | Medical Care
The global market for Castrate Resistant Prostate Cancer Therapeutics was estimated to be worth US$ 18800 million in 2024 and is forecast to a readjusted size of US$ 39170 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
This report aims to provide a comprehensive presentation of the global market for Castrate Resistant Prostate Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Castrate Resistant Prostate Cancer Therapeutics by region & country, by Type, and by Application.
The Castrate Resistant Prostate Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castrate Resistant Prostate Cancer Therapeutics.
Market Segmentation
By Company
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Segment by Type
Hormonal Therapy
Chemotherapy
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Castrate Resistant Prostate Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Castrate Resistant Prostate Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Castrate Resistant Prostate Cancer Therapeutics Product Introduction
1.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Forecast (2020-2031)
1.3 Castrate Resistant Prostate Cancer Therapeutics Market Trends & Drivers
1.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
1.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers & Opportunity
1.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges
1.3.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Players Revenue Ranking (2024)
2.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025)
2.3 Key Companies Castrate Resistant Prostate Cancer Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Castrate Resistant Prostate Cancer Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Castrate Resistant Prostate Cancer Therapeutics
2.6 Castrate Resistant Prostate Cancer Therapeutics Market Competitive Analysis
2.6.1 Castrate Resistant Prostate Cancer Therapeutics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hormonal Therapy
3.1.2 Chemotherapy
3.1.3 Others
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type
3.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value, by Type (2020-2031)
3.2.3 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Specialty Clinic
4.1.3 Others
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application
4.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value, by Application (2020-2031)
4.2.3 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region
5.1.1 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2020-2025)
5.1.3 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2026-2031)
5.1.4 Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
5.2.2 North America Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
5.3.2 Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
5.4.2 Asia Pacific Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
5.5.2 South America Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
5.6.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.3.2 United States Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.4.2 Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.5.2 China Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.6.2 Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.7.2 South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.8.2 Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020-2031
6.9.2 India Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Pfizer/Astellas (Xtandi)
7.1.1 Pfizer/Astellas (Xtandi) Profile
7.1.2 Pfizer/Astellas (Xtandi) Main Business
7.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.1.4 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.1.5 Pfizer/Astellas (Xtandi) Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Profile
7.2.2 Johnson & Johnson Main Business
7.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.2.4 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.2.5 Johnson & Johnson Recent Developments
7.3 AstraZeneca/Merck (Lynparza)
7.3.1 AstraZeneca/Merck (Lynparza) Profile
7.3.2 AstraZeneca/Merck (Lynparza) Main Business
7.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.3.4 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.3.5 AstraZeneca/Merck (Lynparza) Recent Developments
7.4 Bayer
7.4.1 Bayer Profile
7.4.2 Bayer Main Business
7.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.4.4 Bayer Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.4.5 Bayer Recent Developments
7.5 Jiangsu Hengrui Pharmaceuticals
7.5.1 Jiangsu Hengrui Pharmaceuticals Profile
7.5.2 Jiangsu Hengrui Pharmaceuticals Main Business
7.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.5.4 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
7.6 CTTQ
7.6.1 CTTQ Profile
7.6.2 CTTQ Main Business
7.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.6.4 CTTQ Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.6.5 CTTQ Recent Developments
7.7 Sanofi
7.7.1 Sanofi Profile
7.7.2 Sanofi Main Business
7.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.7.4 Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.7.5 Sanofi Recent Developments
7.8 Hansoh
7.8.1 Hansoh Profile
7.8.2 Hansoh Main Business
7.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.8.4 Hansoh Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.8.5 Hansoh Recent Developments
7.9 Clovis Oncology
7.9.1 Clovis Oncology Profile
7.9.2 Clovis Oncology Main Business
7.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.9.4 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.9.5 Clovis Oncology Recent Developments
7.10 Zhendong Pharmaceutical
7.10.1 Zhendong Pharmaceutical Profile
7.10.2 Zhendong Pharmaceutical Main Business
7.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
7.10.4 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) & (2020-2025)
7.10.5 Zhendong Pharmaceutical Recent Developments
8 Industry Chain Analysis
8.1 Castrate Resistant Prostate Cancer Therapeutics Industrial Chain
8.2 Castrate Resistant Prostate Cancer Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Castrate Resistant Prostate Cancer Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Castrate Resistant Prostate Cancer Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Castrate Resistant Prostate Cancer Therapeutics Market Trends
Table 2. Castrate Resistant Prostate Cancer Therapeutics Market Drivers & Opportunity
Table 3. Castrate Resistant Prostate Cancer Therapeutics Market Challenges
Table 4. Castrate Resistant Prostate Cancer Therapeutics Market Restraints
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Castrate Resistant Prostate Cancer Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Castrate Resistant Prostate Cancer Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Castrate Resistant Prostate Cancer Therapeutics
Table 10. Global Castrate Resistant Prostate Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Castrate Resistant Prostate Cancer Therapeutics Sales Market Share in Value by Type (2020-2025)
Table 17. Global Castrate Resistant Prostate Cancer Therapeutics Sales Market Share in Value by Type (2026-2031)
Table 18. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Castrate Resistant Prostate Cancer Therapeutics Sales Market Share in Value by Application (2020-2025)
Table 22. Global Castrate Resistant Prostate Cancer Therapeutics Sales Market Share in Value by Application (2026-2031)
Table 23. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2020-2025) & (%)
Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2026-2031) & (US$ Million)
Table 31. Pfizer/Astellas (Xtandi) Basic Information List
Table 32. Pfizer/Astellas (Xtandi) Description and Business Overview
Table 33. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Pfizer/Astellas (Xtandi) (2020-2025)
Table 35. Pfizer/Astellas (Xtandi) Recent Developments
Table 36. Johnson & Johnson Basic Information List
Table 37. Johnson & Johnson Description and Business Overview
Table 38. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Johnson & Johnson (2020-2025)
Table 40. Johnson & Johnson Recent Developments
Table 41. AstraZeneca/Merck (Lynparza) Basic Information List
Table 42. AstraZeneca/Merck (Lynparza) Description and Business Overview
Table 43. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of AstraZeneca/Merck (Lynparza) (2020-2025)
Table 45. AstraZeneca/Merck (Lynparza) Recent Developments
Table 46. Bayer Basic Information List
Table 47. Bayer Description and Business Overview
Table 48. Bayer Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Bayer (2020-2025)
Table 50. Bayer Recent Developments
Table 51. Jiangsu Hengrui Pharmaceuticals Basic Information List
Table 52. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 53. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Jiangsu Hengrui Pharmaceuticals (2020-2025)
Table 55. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 56. CTTQ Basic Information List
Table 57. CTTQ Description and Business Overview
Table 58. CTTQ Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of CTTQ (2020-2025)
Table 60. CTTQ Recent Developments
Table 61. Sanofi Basic Information List
Table 62. Sanofi Description and Business Overview
Table 63. Sanofi Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Sanofi (2020-2025)
Table 65. Sanofi Recent Developments
Table 66. Hansoh Basic Information List
Table 67. Hansoh Description and Business Overview
Table 68. Hansoh Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Hansoh (2020-2025)
Table 70. Hansoh Recent Developments
Table 71. Clovis Oncology Basic Information List
Table 72. Clovis Oncology Description and Business Overview
Table 73. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Clovis Oncology (2020-2025)
Table 75. Clovis Oncology Recent Developments
Table 76. Zhendong Pharmaceutical Basic Information List
Table 77. Zhendong Pharmaceutical Description and Business Overview
Table 78. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Castrate Resistant Prostate Cancer Therapeutics Business of Zhendong Pharmaceutical (2020-2025)
Table 80. Zhendong Pharmaceutical Recent Developments
Table 81. Key Raw Materials Lists
Table 82. Raw Materials Key Suppliers Lists
Table 83. Castrate Resistant Prostate Cancer Therapeutics Downstream Customers
Table 84. Castrate Resistant Prostate Cancer Therapeutics Distributors List
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Product Picture
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value (2020-2031) & (US$ Million)
Figure 4. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered
Figure 5. Global Castrate Resistant Prostate Cancer Therapeutics Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
Figure 7. Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. Hormonal Therapy Picture
Figure 9. Chemotherapy Picture
Figure 10. Others Picture
Figure 11. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 12. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value Market Share by Type, 2024 & 2031
Figure 13. Product Picture of Hospital
Figure 14. Product Picture of Specialty Clinic
Figure 15. Product Picture of Others
Figure 16. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 17. Global Castrate Resistant Prostate Cancer Therapeutics Sales Value Market Share by Application, 2024 & 2031
Figure 18. North America Castrate Resistant Prostate Cancer Therapeutics Sales Value (2020-2031) & (US$ Million)
Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
Figure 20. Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 21. Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
Figure 22. Asia Pacific Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 23. Asia Pacific Castrate Resistant Prostate Cancer Therapeutics Sales Value by Region (%), 2024 VS 2031
Figure 24. South America Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 25. South America Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
Figure 26. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 27. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Sales Value by Country (%), 2024 VS 2031
Figure 28. Key Countries/Regions Castrate Resistant Prostate Cancer Therapeutics Sales Value (%), (2020-2031)
Figure 29. United States Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 30. United States Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 31. United States Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 32. Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 33. Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 34. Europe Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 35. China Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 36. China Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 37. China Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 38. Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 39. Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 40. Japan Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 41. South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 42. South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 43. South Korea Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 44. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 46. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 47. India Castrate Resistant Prostate Cancer Therapeutics Sales Value, (2020-2031) & (US$ Million)
Figure 48. India Castrate Resistant Prostate Cancer Therapeutics Sales Value by Type (%), 2024 VS 2031
Figure 49. India Castrate Resistant Prostate Cancer Therapeutics Sales Value by Application (%), 2024 VS 2031
Figure 50. Castrate Resistant Prostate Cancer Therapeutics Industrial Chain
Figure 51. Castrate Resistant Prostate Cancer Therapeutics Manufacturing Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
